Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine.
Subjects > or = 55 years of age were immunized with attenuated varicella zoster virus (VZV) vaccine (live) or with the same vaccine, which had been heated to 56 degrees C for 7 days (killed). The ability of subjects' blood lymphocytes to lyse target cells infected with VZV was determined before and 3 months after immunization using autologous Epstein-Barr virus (EBV) lymphoblasts as targets for human leukocyte antigen (HLA) class I restricted cytotoxicity and human fibroblasts as targets for unrestricted (natural killer [NK]) cytotoxicity. The live vaccine recipients showed an increase in their class I-restricted lysis of targets compared with the recipients of the killed vaccine. The two populations showed equivalent increase in their NK-dependent lysis of fibroblast targets. The results support the view that both the live and killed vaccines stimulate cytotoxicity by VZV-specific lymphocytes but that the live vaccine stimulates relatively more class I-restricted killing.
Hayward
A R
AR
Department of Pediatrics, University of Colorado School of Medicine, Denver, USA.
Buda
K
K
Jones
M
M
White
C J
CJ
Levin
M J
MJ
D000368:Aged; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D002478:Cells, Cultured; D003601:Cytotoxicity Tests, Immunologic; D014645:Herpesvirus 3, Human / Q000276:immunology*; D004854:Herpesvirus 4, Human / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007694:Killer Cells, Natural / Q000276:immunology*; D008875:Middle Aged; D014613:Vaccines, Attenuated / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D015395:Histocompatibility Antigens Class I; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C070916:glycoprotein IV, varicella-zoster virus